XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 14, 2022
Entity Listings [Line Items]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Form 8-K/A is being filed as an amendment (the “Amendment”) to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 14, 2022 (“Original Filing”). The sole purpose of this Amendment is to furnish Exhibit 10.1, which was inadvertently omitted in the Original Filing as a result of a clerical error. Other than as described above, this Amendment does not modify or update any disclosures in or exhibits to the Original Filing nor does it reflect any events that may have occurred subsequent to the Original Filing.
Document Period End Date Nov. 14, 2022
Entity File Number 001-38807
Entity Registrant Name Chemomab Therapeutics Ltd.
Entity Central Index Key 0001534248
Entity Incorporation, State or Country Code L3
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One Kiryat Atidim, Building 7
Entity Address, City or Town Tel Aviv
Entity Address, Country IL
Entity Address, Postal Zip Code 6158002
City Area Code 972
Local Phone Number 77-331-0156
Entity Emerging Growth Company true
Entity Ex Transition Period false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share
Trading Symbol CMMB
Security Exchange Name NASDAQ
Ordinary shares, no par value per share [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Ordinary shares, no par value per share
Trading Symbol N/A
Security Exchange Name NASDAQ